SecBot SecBot
SC 13G/A ·Filed Oct 30, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Processed1h 26m ago SEC0002100121-26-001144
Passive stake amendment

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0002100121-26-001144
Document: 0002100121-26-001144-index.html0002100121-26-001144
Document: 0002100121-26-001144.txt0002100121-26-001144
18 reports for RARE
Performance horizon
78% Hit rate @ T+5 7 of 9 directional calls Went positive at some point 8 of 9 best @ T+60▲ +48.73%Apr 2, 2026
Filters
Rows
Reports for RARE, sortable and filterable
TypeNow
Oct 30, 2026
today
SC 13G/A
NEUTRAL ★ 2/10
$16.07awaiting T+5awaiting T+5$16.16 (+0.56%)
Oct 20, 2026
9d ago
SC 13G
NEUTRAL ★ 3/10
$15.92 $16.75▲ +5.21%▲ +5.66%$16.16 (+1.51%)
Oct 19, 2026
11d ago
8-K
NEUTRAL ★ 4/10
$15.07 $16.08▲ +6.70%▲ +6.85%$16.16 (+7.23%)
Oct 14, 2026
16d ago
8-K
BULLISH ★ 6/10
$14.90 $15.92▲ +6.85%▲ +6.39%$16.16 (+8.46%)
Oct 7, 2026
23d ago
8-K
BULLISH ★ 6/10
$14.89 $14.90▲ +0.07%▲ +1.05%$16.16 (+8.53%)
Sep 17, 2026
6w ago
Press Release
BULLISH ★ 8/10
$14.50 $14.77▲ +1.86%▲ +1.01%$16.16 (+11.45%)
Sep 2, 2026
8w ago
8-K
BEARISH ★ 8/10
$14.85 $14.30▲ +3.70%▲ +2.56%$16.16 (−8.82%)
Sep 1, 2026
8w ago
Press Release
BULLISH ★ 7/10
$26.53 $14.40▼ −45.72%▼ −44.76%$16.16 (−39.09%)
Aug 11, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$26.80 $25.49▼ −4.89%▼ −4.48%$16.16 (−39.70%)
Aug 4, 2026
12w ago
8-K
BULLISH ★ 6/10
$24.93 $26.86▲ +7.74%▲ +7.39%$16.16 (−35.18%)
Showing 10 of 18

US Market Status

Market Open · Closes in 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026

Fresh RARE Intelligence

Analysis is for subscribers only.

Subscribe for Full Access